Real-Time MRI-Guided Prostate Interventions

Masoom, Seyedeh Nina; Sundaram, K.; Ghanouni, Pejman; Fütterer, Jurgen J.; Oto, Aytekin; Ayyagari, Raj; Sprenkle, Preston; Weinreb, Jeffrey C.; Arora, Sandeep

doi:10.3390/cancers14081860

Cited by 12 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In-bore MRI-guided prostate biopsy in patients with suspected prostate cancer has been documented in the literature. 19,20 In-bore MRI-guided prostate biopsy uses MRI technology to guide transperineal prostate biopsy, which is suitable for patients without rectums. No current literature is available on head-to-head comparisons of MRI-guided and CT-guided methods.…”

Section: Discussionmentioning

confidence: 99%

Computed Tomography–Guided Prostate Sampling and Fiducial Marker Insertion in Patients With Absent Rectums

Chau¹,

Saluja²,

Anderson

2023

J Comput Assist Tomogr

View full text Add to dashboard Cite

Objectives We aimed to present our experience and the outcomes of a novel technique, computed tomography (CT)–guided prostate biopsy and fiducial marker insertion in patients with absent rectums. Methods Patients who underwent CT-guided prostate biopsy at a single institution from November 2010 to November 2022 were retrospectively reviewed. Patients were included if they had a clinical suspicion of prostate cancer and had absent rectums from previous surgical resection. Contrast-enhanced CT scan was used to perform transgluteal prostate biopsy. Patient demographics, multiparametric magnetic resonance imaging, and biopsy details were recorded. Results Thirteen biopsy procedures and 1 CT-guided fiducial marker insertion were performed on 12 unique patients. The reasons for the absence of rectums included surgical resection for rectal cancer (n = 10) and surgical resection for inflammatory bowel disease (n = 2). Clinically significant cancer was found in 7 of 13 biopsy results (52.8%), clinically insignificant cancer in 3 of 13 (23.1%), and benign cancer in 3 of 13 (23.1%). No complications were recorded. Conclusions Our data support CT-guided prostate biopsy as an accurate and effective technique for investigating prostate cancer that requires tissue sampling in patients with absent rectums.

show abstract

Section: Discussionmentioning

confidence: 99%

Computed Tomography–Guided Prostate Sampling and Fiducial Marker Insertion in Patients With Absent Rectums

Chau¹,

Saluja²,

Anderson

2023

J Comput Assist Tomogr

View full text Add to dashboard Cite

show abstract

“…Radiological imaging techniques, such as multiparametric magnetic resonance imaging (mpMRI), and nuclear medicine methods, notably skeletal scintigraphy and positron emission tomography (PET) utilizing 68 Ga prostate-specific membrane antigen (PSMA) ligands, play pivotal roles in diagnosing the advanced stages of PC [5]. There is also an increasing focus on the MRI-guided prostate biopsy [6]. Metastatic castration-resistant prostate cancer (mCRPC) represents the terminal stage of PC, characterized by the failure of antiandrogen therapy and distant metastases predominantly to the skeleton [7].…”

Section: Introductionmentioning

confidence: 99%

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Evin,

Evinová,

Baranovičová

et al. 2024

IJMS

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease due to the absence of effective therapies. A more comprehensive understanding of molecular events, encompassing the dysregulation of microRNAs (miRs) and metabolic reprogramming, holds the potential to unveil precise mechanisms underlying mCRPC. This study aims to assess the expression of selected serum exosomal miRs (miR-15a, miR-16, miR-19a-3p, miR-21, and miR-141a-3p) alongside serum metabolomic profiling and their correlation in patients with mCRPC and benign prostate hyperplasia (BPH). Blood serum samples from mCRPC patients (n = 51) and BPH patients (n = 48) underwent metabolome analysis through 1H-NMR spectroscopy. The expression levels of serum exosomal miRs in mCRPC and BPH patients were evaluated using a quantitative real-time polymerase chain reaction (qRT-PCR). The 1H-NMR metabolomics analysis revealed significant alterations in lactate, acetate, citrate, 3-hydroxybutyrate, and branched-chain amino acids (BCAAs, including valine, leucine, and isoleucine) in mCRPC patients compared to BPH patients. MiR-15a, miR-16, miR-19a-3p, and miR-21 exhibited a downregulation of more than twofold in the mCRPC group. Significant correlations were predominantly observed between lactate, citrate, acetate, and miR-15a, miR-16, miR-19a-3p, and miR-21. The importance of integrating metabolome analysis of serum with selected serum exosomal miRs in mCRPC patients has been confirmed, suggesting their potential utility for distinguishing of mCRPC from BPH.

show abstract

Section: Introductionmentioning

confidence: 99%

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Evin,

Evinová,

Baranovičová

et al. 2024

Preprint

View full text Add to dashboard Cite

Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease due to the absence of effective therapies. A more comprehensive understanding of molecular events, encompassing the dysregulation of microRNAs (miRs) and metabolic reprogramming, holds the potential to unveil precise mechanisms underlying mCRPC. This study aims to assess the expression of selected serum exosomal miRs (miR-15a, miR-16, miR-19a-3p, miR-21, and miR-141a-3p) alongside serum metabolomic profiling and their correlation in patients with mCRPC and benign prostate hyperplasia (BPH). Blood serum samples from mCRPC patients (n=51) and BPH patients (n=48) underwent metabolome analysis through 1H-NMR spectroscopy. The expression levels of serum exosomal miRs in mCRPC and BPH patients were evaluated using quantitative real-time polymerase chain reaction (qRT‒PCR). The 1H-NMR metabolomics analysis revealed significant alterations in lactate, acetate, citrate, 3-hydroxybutyrate, and branched-chain amino acids (BCAAs, including valine, leucine, and isoleucine) in mCRPC patients compared to BPH patients. MiR-15a, miR-16, miR-19a-3p, and miR-21 exhibited a down-regulation of more than twofold in the mCRPC group. Significant correlations were predominantly observed between lactate, citrate, acetate, and miR-15a, miR-16, miR-19a-3p, and miR-21. The importance of integrating metabolome analysis of serum with selected serum exosomal miRs in mCRPC patients has been confirmed, suggesting their potential utility as clinical diagnostic markers.

show abstract

Real-Time MRI-Guided Prostate Interventions

Cited by 12 publications

References 36 publications

Computed Tomography–Guided Prostate Sampling and Fiducial Marker Insertion in Patients With Absent Rectums

Computed Tomography–Guided Prostate Sampling and Fiducial Marker Insertion in Patients With Absent Rectums

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About